Meeting
2023 ASCO Annual Meeting
Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition.
Authors
Rik Jasper Verheijden
University Medical Center Utrecht, Utrecht, Netherlands
Rik Jasper Verheijden , Anna Cabane Ballester , Mick JM van Eijs , Anne SR van Lindert , Karijn Suijkerbuijk , Anne Maria May
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2643)
DOI
10.1200/JCO.2023.41.16_suppl.2643
Abstract #
2643
Poster Bd #
485
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic impact of immune-related adverse events on survival outcomes in metastatic gastrointestinal cancer: A single-institutional experience.
First Author: Olisaemeka Ogbue
Poster
2020 ASCO Virtual Scientific Program
Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.
First Author: Richard Lee O'Neal
Poster
2018 ASCO Annual Meeting
Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials.
First Author: Shiraj Sen